A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

NCT07244705 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer (Diagnosis)
Colorectal Cancer Metastatic
Colorectal Cancer (CRC)
Immunotherapy

Interventions

DRUG: ABT-301
DRUG: Tislelizumab
DRUG: Bevacizumab (Avastin)

Sponsor

Anbogen Therapeutics, Inc.

Collaborators

[object Object]